Immunotherapy (Sintilimab)

DRUG2 trials

Sponsors

Shandong Cancer Hospital and Institute, First Affiliated Hospital of Wenzhou Medical University

Conditions

Colorectal CancerHR+/HER2- Breast CancerImmunotherapyLiver MetastasisRadiotherapyTargeted Therapy

Phase 2

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

RecruitingNCT06356584

Shandong Cancer Hospital and InstituteColorectal Cancer, Immunotherapy, Liver Metastasis +2

Start: 2024-04-01End: 2026-10-01Target: 62Updated: 2025-06-26

Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer

Not yet recruitingNCT07254858

First Affiliated Hospital of Wenzhou Medical UniversityHR+/HER2- Breast Cancer

Start: 2025-12-31End: 2029-12-30Target: 302Updated: 2025-11-28